ECE2016 Eposter Presentations Diabetes therapy (44 abstracts)
GLP-1-RAs treatment in type 2 diabetes and obesity patients
Jose Alvaro Romero Porcel , Eyvee Arturo Cuellar Lloclla , Guillermo Martinez de Pinillos Gordillo , Fernando Garcia Perez , Mariola Mendez Muros , Jose Ignacio Fernández Peña , Mariana Tome Fernandez-Ladreda , Juan Manuel Garcia de Quiros , Jose Ignacio Fernandez Lopez & Maria Victoria Cozar Leon
Hospital Universitario de Valme, Seville, Spain.
Introduction: Assessing the effect of GLP 1 receptor agonist on metabolic control and weight loss in obesity and type 2 diabetes patients.
Description of methods: A retrospective descriptive study involving type 2 diabetes patients and BMI >30 kg/m2, who started treatment with GLP-1-RAs during the years 2012–2014. Variables analyzed: weight and HbA1c at the begging, 6 months, 1 and 2 years; regimen at baseline and after GLP-1-RAs; incidence of withdrawal of treatment.
Results: 125 patients were included (mean age 55.4±9.7 years old; male 58.4%). GLP-1 agonists: exenatide 24.8%, liraglutide 57.6%, 17.6% lixisenatide. HbA1c at baseline: 8.9±1.37%; HbA1c 6 months: 7.7%±1.3; HbA1c 1 year: 7.3%±1.4; HbA1c 2 years: 7.3%±1.3. Start weight: 16.4±106.4 kg; 6 months weight: 101.6±16.5 kg; 1 year weight: 15.7±98.4 kg; 2 years weight: 15.5±97.4 kg. The difference in HbA1c and weight at baseline and 6 months, 1 year and 2 years follow-up statistically significant (P<0.001), not statistically significant difference the first and second years of therapy. 56.8% patients were treated with insulin at start. After addition GLP-1-RAs insulin treatment was finished by 9.9% (45.2% basal bolus therapy who changed baseline insuline and OADs). Therapy discontinued in 25.6% (68.8% in the first-year), the main reason was non-response (75%).
Conclusions: GLP-1 agonist inclusion in type 2 diabetes therapy improves glycemic blood control and loss weight. Improvement already 6 months and holding the first and second year. Treatment helped simplified insulinize, which is reflected in that almost half of those doing intensive treatment could suspend insulin. However, the number of patients we found in whom the treatment brought no improvement was significant, been observed early non-response.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more